Radiochemical and preliminary biological comparison of a 3p-C-NETA-GA-PSMA derivative

Erika Murce; Stephen Ahenkorah; S. Beekman; Lilian van den Brink; Simone Dalm; Frederik Cleeren; Yann Seimbille

doi:10.1007/s00259-022-05924-4.pdf?pdf=button

Radiochemical and preliminary biological comparison of a 3p-C-NETA-GA-PSMA derivative

Erika Murce, Stephen Ahenkorah, S. Beekman, Lilian van den Brink, Simone Dalm, Frederik Cleeren, Yann Seimbille

Research output › peer-review

Abstract

Prostate specific membrane antigen (PSMA) targeting radiopharmaceuticals have been successfully used for diagnosis and therapy of prostate cancer, as illustrated by PSMA-617 (PluvictoTM). Development of optimized PSMA-targeting probes has focused on theranostic (therapy + diagnosis) approaches, where the same precursor can be radiolabeled with similar or identical nuclides, allowing for personalised dosimetry estimation and radionuclide therapy of patients. 3p-C-NETA is a promising chelator which has been shown to efficiently label therapeutic (177Lu, 161Tb, 213Bi) and diagnostic (68Ga, Al18F) nuclides1. In this study, we attached this chelator to a PSMA-targeting derivative and compared it to a derivative containing a DOTA-GA chelator and to the gold standard PSMA-617.

Original language	English
Title of host publication	European Journal of Nuclear Medicine and Molecular Imaging
Subtitle of host publication	Annual Congress of the European Association of Nuclear Medicine October 15-19, 2022 Barcelona, Spain
Publisher	Springer Link
Pages	S425
Number of pages	1
Volume	49
DOIs	https://doi.org/10.1007/s00259-022-05924-4.pdf?pdf=button
State	Published - 22 Sep 2022

Publication series

Name	European Journal of Nuclear Medicine and Molecular Imaging
Publisher	Springer Link
Number	EP-005
Volume	49
ISSN (Print)	1619-7070
ISSN (Electronic)	1619-7089

Access to Document

10.1007/s00259-022-05924-4.pdf?pdf=buttonLicense: Unspecified

Cite this

Murce, E., Ahenkorah, S., Beekman, S., van den Brink, L., Dalm, S., Cleeren, F., & Seimbille, Y. (2022). Radiochemical and preliminary biological comparison of a 3p-C-NETA-GA-PSMA derivative. In European Journal of Nuclear Medicine and Molecular Imaging: Annual Congress of the European Association of Nuclear Medicine October 15-19, 2022 Barcelona, Spain (Vol. 49, pp. S425). Article EP-005 (European Journal of Nuclear Medicine and Molecular Imaging; Vol. 49, No. EP-005). Springer Link. https://doi.org/10.1007/s00259-022-05924-4.pdf?pdf=button

Murce, Erika ; Ahenkorah, Stephen ; Beekman, S. et al. / Radiochemical and preliminary biological comparison of a 3p-C-NETA-GA-PSMA derivative. European Journal of Nuclear Medicine and Molecular Imaging: Annual Congress of the European Association of Nuclear Medicine October 15-19, 2022 Barcelona, Spain. Vol. 49 Springer Link, 2022. pp. S425 (European Journal of Nuclear Medicine and Molecular Imaging; EP-005).

@inproceedings{1836c42b5f2c4d7e9eccc57320fe8c5c,

title = "Radiochemical and preliminary biological comparison of a 3p-C-NETA-GA-PSMA derivative",

abstract = "Prostate specific membrane antigen (PSMA) targeting radiopharmaceuticals have been successfully used for diagnosis and therapy of prostate cancer, as illustrated by PSMA-617 (PluvictoTM). Development of optimized PSMA-targeting probes has focused on theranostic (therapy + diagnosis) approaches, where the same precursor can be radiolabeled with similar or identical nuclides, allowing for personalised dosimetry estimation and radionuclide therapy of patients. 3p-C-NETA is a promising chelator which has been shown to efficiently label therapeutic (177Lu, 161Tb, 213Bi) and diagnostic (68Ga, Al18F) nuclides1. In this study, we attached this chelator to a PSMA-targeting derivative and compared it to a derivative containing a DOTA-GA chelator and to the gold standard PSMA-617.",

keywords = "3p-C-NETA, PSMA-targeted radionuclide therapy",

author = "Erika Murce and Stephen Ahenkorah and S. Beekman and {van den Brink}, Lilian and Simone Dalm and Frederik Cleeren and Yann Seimbille",

note = "Score=3",

year = "2022",

month = sep,

day = "22",

doi = "10.1007/s00259-022-05924-4.pdf?pdf=button",

language = "English",

volume = "49",

series = "European Journal of Nuclear Medicine and Molecular Imaging",

publisher = "Springer Link",

number = "EP-005",

pages = "S425",

booktitle = "European Journal of Nuclear Medicine and Molecular Imaging",

}

Murce, E, Ahenkorah, S, Beekman, S, van den Brink, L, Dalm, S, Cleeren, F & Seimbille, Y 2022, Radiochemical and preliminary biological comparison of a 3p-C-NETA-GA-PSMA derivative. in European Journal of Nuclear Medicine and Molecular Imaging: Annual Congress of the European Association of Nuclear Medicine October 15-19, 2022 Barcelona, Spain. vol. 49, EP-005, European Journal of Nuclear Medicine and Molecular Imaging, no. EP-005, vol. 49, Springer Link, pp. S425. https://doi.org/10.1007/s00259-022-05924-4.pdf?pdf=button

Radiochemical and preliminary biological comparison of a 3p-C-NETA-GA-PSMA derivative. / Murce, Erika; Ahenkorah, Stephen; Beekman, S. et al.
European Journal of Nuclear Medicine and Molecular Imaging: Annual Congress of the European Association of Nuclear Medicine October 15-19, 2022 Barcelona, Spain. Vol. 49 Springer Link, 2022. p. S425 EP-005 (European Journal of Nuclear Medicine and Molecular Imaging; Vol. 49, No. EP-005).

Research output › peer-review

TY - GEN

T1 - Radiochemical and preliminary biological comparison of a 3p-C-NETA-GA-PSMA derivative

AU - Murce, Erika

AU - Ahenkorah, Stephen

AU - Beekman, S.

AU - van den Brink, Lilian

AU - Dalm, Simone

AU - Cleeren, Frederik

AU - Seimbille, Yann

N1 - Score=3

PY - 2022/9/22

Y1 - 2022/9/22

N2 - Prostate specific membrane antigen (PSMA) targeting radiopharmaceuticals have been successfully used for diagnosis and therapy of prostate cancer, as illustrated by PSMA-617 (PluvictoTM). Development of optimized PSMA-targeting probes has focused on theranostic (therapy + diagnosis) approaches, where the same precursor can be radiolabeled with similar or identical nuclides, allowing for personalised dosimetry estimation and radionuclide therapy of patients. 3p-C-NETA is a promising chelator which has been shown to efficiently label therapeutic (177Lu, 161Tb, 213Bi) and diagnostic (68Ga, Al18F) nuclides1. In this study, we attached this chelator to a PSMA-targeting derivative and compared it to a derivative containing a DOTA-GA chelator and to the gold standard PSMA-617.

AB - Prostate specific membrane antigen (PSMA) targeting radiopharmaceuticals have been successfully used for diagnosis and therapy of prostate cancer, as illustrated by PSMA-617 (PluvictoTM). Development of optimized PSMA-targeting probes has focused on theranostic (therapy + diagnosis) approaches, where the same precursor can be radiolabeled with similar or identical nuclides, allowing for personalised dosimetry estimation and radionuclide therapy of patients. 3p-C-NETA is a promising chelator which has been shown to efficiently label therapeutic (177Lu, 161Tb, 213Bi) and diagnostic (68Ga, Al18F) nuclides1. In this study, we attached this chelator to a PSMA-targeting derivative and compared it to a derivative containing a DOTA-GA chelator and to the gold standard PSMA-617.

KW - 3p-C-NETA

KW - PSMA-targeted radionuclide therapy

UR - https://link.springer.com/content/pdf/10.1007/s00259-022-05924-4.pdf?pdf=button

U2 - 10.1007/s00259-022-05924-4.pdf?pdf=button

DO - 10.1007/s00259-022-05924-4.pdf?pdf=button

M3 - In-proceedings paper

VL - 49

T3 - European Journal of Nuclear Medicine and Molecular Imaging

SP - S425

BT - European Journal of Nuclear Medicine and Molecular Imaging

PB - Springer Link

ER -

Murce E, Ahenkorah S, Beekman S, van den Brink L, Dalm S, Cleeren F et al. Radiochemical and preliminary biological comparison of a 3p-C-NETA-GA-PSMA derivative. In European Journal of Nuclear Medicine and Molecular Imaging: Annual Congress of the European Association of Nuclear Medicine October 15-19, 2022 Barcelona, Spain. Vol. 49. Springer Link. 2022. p. S425. EP-005. (European Journal of Nuclear Medicine and Molecular Imaging; EP-005). doi: 10.1007/s00259-022-05924-4.pdf?pdf=button